CN115322176B - 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 - Google Patents
一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 Download PDFInfo
- Publication number
- CN115322176B CN115322176B CN202111257234.0A CN202111257234A CN115322176B CN 115322176 B CN115322176 B CN 115322176B CN 202111257234 A CN202111257234 A CN 202111257234A CN 115322176 B CN115322176 B CN 115322176B
- Authority
- CN
- China
- Prior art keywords
- reaction
- mmol
- added
- synthesis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 2, 3-dihydrobenzofuranyl Chemical group 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 abstract description 11
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract description 11
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract description 11
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract description 8
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 7
- 102000020233 phosphotransferase Human genes 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 145
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 66
- 230000015572 biosynthetic process Effects 0.000 description 48
- 238000003786 synthesis reaction Methods 0.000 description 48
- 238000010898 silica gel chromatography Methods 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 33
- 235000019341 magnesium sulphate Nutrition 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 20
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 14
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 10
- 238000001819 mass spectrum Methods 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 230000005311 nuclear magnetism Effects 0.000 description 10
- 238000005086 pumping Methods 0.000 description 10
- 238000012795 verification Methods 0.000 description 10
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- HGXWRDPQFZKOLZ-UHFFFAOYSA-N 4-bromo-2-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC=C1C#N HGXWRDPQFZKOLZ-UHFFFAOYSA-N 0.000 description 4
- WMKDUJVLNZANRN-UHFFFAOYSA-N 6-bromo-1h-indazole Chemical compound BrC1=CC=C2C=NNC2=C1 WMKDUJVLNZANRN-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 4
- 102100029203 F-box only protein 8 Human genes 0.000 description 4
- 101100334493 Homo sapiens FBXO8 gene Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IXLCEJNZWAYHPL-UHFFFAOYSA-N 1-phenylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=CC=C1 IXLCEJNZWAYHPL-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- HBMCPFPBUXHGEL-UHFFFAOYSA-N tert-butyl 3-amino-6-bromoindazole-1-carboxylate Chemical compound C1=C(Br)C=C2N(C(=O)OC(C)(C)C)N=C(N)C2=C1 HBMCPFPBUXHGEL-UHFFFAOYSA-N 0.000 description 2
- ISIFPVOJHJASJW-UHFFFAOYSA-N (4-fluorophenyl)methylurea Chemical compound NC(=O)NCC1=CC=C(F)C=C1 ISIFPVOJHJASJW-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- VTFFHIADUQVPPO-UHFFFAOYSA-N 4-(4-ethylpiperazin-1-yl)benzamide Chemical compound C1CN(CC)CCN1C1=CC=C(C(N)=O)C=C1 VTFFHIADUQVPPO-UHFFFAOYSA-N 0.000 description 1
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 1
- NMAOAFBQWWLHQG-UHFFFAOYSA-N 4-methylpiperazine-1-sulfonamide Chemical compound CN1CCN(S(N)(=O)=O)CC1 NMAOAFBQWWLHQG-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- 102100028175 Abasic site processing protein HMCES Human genes 0.000 description 1
- 102100022210 COX assembly mitochondrial protein 2 homolog Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940125830 FGFR1 inhibitor Drugs 0.000 description 1
- 101001006387 Homo sapiens Abasic site processing protein HMCES Proteins 0.000 description 1
- 101000900446 Homo sapiens COX assembly mitochondrial protein 2 homolog Proteins 0.000 description 1
- 101000631695 Homo sapiens Succinate dehydrogenase assembly factor 3, mitochondrial Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100028996 Succinate dehydrogenase assembly factor 3, mitochondrial Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药物化学领域,具体涉及一种2,3‑二氢苯并呋喃基取代的1H‑吲唑类化合物及其制备和应用,该类化合物可以选择性的抑制FGFR激酶的磷酸化,从而治疗与此激酶密切相关的恶性肿瘤,同时能减少不良反应;能够用于治疗FGFR酶相关的肿瘤或疾病。本发明中所公开的化合物如通式(1)表示。其中R1可以多种取代基选择。本发明所述的以FGFR为靶点的N‑取代苯甲酰胺类化合物对FGFR1激酶具有良好的抑制作用;可用于抗肿瘤药物,且抗肿瘤效果较好。
Description
技术领域
本发明属于医药化学技术领域,尤其涉及一种N-取代(3-((6-(2,3-二氢苯并呋喃-5-基)-1H-吲唑-3-基)氨基)苯甲酰胺类结靶向FGFR 1小分子抑制剂及其制备和抗肿瘤活性的应用。
背景技术
近十几年来,靶向治疗成为癌症治疗的研究热点之一,在靶向治疗中,酪氨酸激酶家族与肿瘤的发病有着密切的关系,蛋白激酶参与调节对细胞生长、增殖和生存至关重要的信号网络。在酪氨酸激酶家族中,表皮生长因子受体(epidermal growth factorreceptor,EGFR)备受关注。第一代EGFR抑制剂如吉非替尼(Gefitinib)和厄洛替尼(Erlotinib)治疗NSCLC患者一段时间后,不少患者都产生了对EGFR-TKI的耐药。
EGFR-TKI的耐药过程,触发了其他促增殖的受体酪氨酸激酶信号通路的激活。如FGFR和ALK通路。
成纤维生长因子受体(Fibroblast growth factor receptor,FGFRs)介导的信号通路,不仅对于正常细胞的增殖、分化发挥作用,对于肿瘤细胞的生长和转移更是发挥重要的调节作用。FGFRs作为重要的抗肿瘤药物作用靶点,其小分子抑制剂的研发受到越来越多的重视。
在FGFR的四种类型中,FGFR1与肺癌关系最密切。大量体外研究和独立实验表明在非小细胞肺癌中存在FGFR1的基因扩增和FGFR1的过表达。在一项对59个非小细胞肺癌病人的肿瘤组织和癌旁组织的定量RT-PCR实验中发现,肿瘤组织FGFR1的转录活性是癌旁组织的两倍多。吉非替尼耐药会激活FGFR通路(FGF2-FGFR1)。揭示FGF/FGFR的自分泌环的活化是促进阿法替尼耐药细胞存活和生长的补偿机制。
发明内容
本发明提供了一种2,3-二氢苯并呋喃基取代的1H-吲唑类化合物及其制备和抗肿瘤活性的应用,该N-取代(4-(4-乙基哌嗪-1-基)苯基)-6-苯基-1H-吲唑-3-胺类靶向FGFR1抑制剂对FGFR 1具有较高的抑制活性,可以作为一种潜在的抗肿瘤药物。
本发明采用如下技术方案:
一种2,3-二氢苯并呋喃基取代的1H-吲唑类化合物靶向FGFR1小分子抑制剂,化学结构如下:
其中:R1基团可以选自下列任一取代基团
R2可以选自H或Boc中的任意一种;以上R1、R2的取代基可以任意组合。
进一步地,所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物靶向DDR1小分子抑制剂为化合物DC1-DC13中的一种,DC1-DC13中的R2如表1-1所示:
表1-1化合物DC1-DC13结构与产率
化合物 | R2 |
DC1 | N-(2-(diethylamino)ethyl) |
DC2 | N-(3-(4-methylpiperazin-1-yl)phenyl |
DC3 | Furan-2-carboxamide |
DC4 | 4-(4-ethylpiperazin-1-yl)benzamide |
DC5 | N-(4-(4-ethylpiperazin-1-yl)benzyl) |
DC6 | 4-methylpiperidine |
DC7 | 4-ethylpiperazine |
DC8 | 2-formyl-1H-pyrrole-1-carboxamide |
DC9 | (4-fluorobenzyl)urea |
DC10 | 1-phenylpiperidine |
DC11 | 4-methoxybenzenesulfonamide |
DC12 | 4-methylpiperazine-1-sulfonamide |
DC13 | 3-phenylpropanamide |
进一步的,所述的化合物为化合物DC4,化学结构如下:
本发明还提供了一种所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物的制备方法,包括以下步骤:
DC1,2,4合成步骤
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(10.15mmol)6-溴吲唑溶于20mL的无水THF,在冰浴下多次少量加入2.28g(20.30mmol)KOtBu,活化10分钟后再加入3.9g(15.37mmol)碘单质。在冰浴下继续反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL双颈瓶,放入搅拌子。称取1.4g(3.32mmol)中间体2,680mg N-乙基哌嗪苯胺,30.4mg(0.00332mmol)Pd2(dba)3,38.4mg(0.00664mmol)Xantphos,2.16g(6.64mmol)碳酸铯。用三通阀抽真空,氮气置换三次,用注射器加入20mL的甲苯,在70℃下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为6h。反应结束后,用EtOAc萃取(3×30mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体3。
(4)化合物D1、D2、D4的合成通法:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物D1、D2、D4。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
DC5合成步骤
1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(10.15mmol)6-溴吲唑溶于20mL的无水THF,在冰浴下多次少量加入2.28g(20.30mmol)KOtBu,活化10分钟后再加入3.9g(15.37mmol)碘单质。在冰浴下继续反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL双颈瓶,放入搅拌子。称取1.4g(3.32mmol)中间体2,680mg N-乙基哌嗪苯胺,30.4mg(0.00332mmol)Pd2(dba)3,38.4mg(0.00664mmol)Xantphos,2.16g(6.64mmol)碳酸铯。用三通阀抽真空,氮气置换三次,用注射器加入20mL的甲苯,在70℃下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为6h。反应结束后,用EtOAc萃取(3×30mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体3。
(4)中间体4的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体4。
(5)DC5的合成:取一个50mL两口烧瓶,取60.8mg(1.2mmol)的LAH,氮气保护,加入15mL的无水THF,在-78℃缓慢加入(0.4mmol)溶于无水THF的中间体4,加完后移至室温后过夜,用TLC监测反应进程判断反应终点。减压浓缩,硅胶柱层析进一步纯化得产物DC5。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
DC3,11-13合成步骤
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子,将2.02g(10.15mmol)4-溴-2-氟苯甲腈溶于20mL的无水正丁醇,再加入1.015g(20.30mmol)水合肼,于120℃下冷凝回流。用TLC监测反应进程判断反应终点,反应时间一般为5h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL双颈瓶,放入搅拌子。称取1.4g(3.32mmol)中间体2,680mg N-乙基哌嗪苯胺,30.4mg(0.00332mmol)Pd2(dba)3,38.4mg(0.00664mmol)Xantphos,2.16g(6.64mmol)碳酸铯。用三通阀抽真空,氮气置换三次,用注射器加入20mL的甲苯,在70℃下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为6h。反应结束后,用EtOAc萃取(3×30mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体3。
(4)中间体4的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物DC3,DC11-DC13。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
DC10合成步骤
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子,将2.02g(10.15mmol)4-溴-2-氟苯甲腈溶于20mL的无水正丁醇,再加入1.015g(20.30mmol)水合肼,于120℃下冷凝回流。用TLC监测反应进程判断反应终点,反应时间一般为5h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子,并加入25mL的无水CH2Cl2。将0.5g(2.44mmol)的1-苯基哌啶-4-羧酸加入反应瓶中,再加入1.113g(2.928mmol)的HATU和0.436(2.928mmol)TEA,30min后加入0.974g(2.44mmol)的中间体2,用TLC监测反应进程判断反应终点。
(4)DC10的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。
步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物DC10。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
DC6-9合成步骤
(1)中间体1的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。加入1mmol(311mg)的3-氨基-6-溴-1H-吲唑-1-羧酸叔丁酯,同时溶于无水THF15mL,再加入100mg的DIEPA,加入搅拌子,冰浴搅拌15min,后逐滴加入1.2mmol的酰氯,同时每隔半个小时点板监测,直至原料点不变或消失。反应结束后用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。再加入15mL的无水DMF于双颈瓶中,冰浴冷却至0℃,再加入1mmol的中间体1和2mmol的K2CO3,反应30min,同时每隔5min点板监测,直至原料点不变或消失。反应结束后用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2,直接用于下一步。
(3)中间体3的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物DC3,DC11-DC13。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
本发明还提供了一种所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物在制备抗肿瘤药物中的应用。
本发明的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物抑制剂表现出一定的抗肿瘤活性。
作为进一步的优选,所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物为化合物D5。
作为进一步的优选,所述的抗肿瘤药物用于治疗结肠癌或非小细胞肺癌。
同现有技术相比,本发明的有益效果体现在:
本发明提供了一类新的靶向FGFR1小分子抑制剂,该小分子抑制剂能有效抑制DDR1,可以作为一种有潜力的抗癌药物进行开发和研究。
具体实施方式
下面的实施例是对本发明的进一步详细描述。
实施例1化合物的合成
1.1化合物的具体合成路线(路线中所列的碱、溶剂和缚酸剂仅仅为示例性的,不是对本发明的限制)如下所示:
反应式1.化合物DC1,2,4,5的一般合成方法
反应试剂和反应条件:(a)iodine,KOtBu,THF,0℃,2h;(b)(Boc)2O,DMAP,THF,rt,2h;(c)Pd2(dba)3,Xantphos,Cs2CO3,N2,toluene,6h.(d)Pd(pph3)4,NaOH,dioxane:H2O(4:1),N2,90℃,overnight.(e)THF,DIPEA,0℃to rt,3h.(f)Pd/C,H2,MeOH,4h.(g)DMSO,K2CO3,120℃,8h.(h)35%H2O2,DMSO,K2CO3.(i)LAH,THF,-78℃.
反应式2.化合物DC3,10-13的一般合成方法
反应试剂和反应条件:(a)Hydrazine hydrate,n-butanol,120℃,5 h;(b)(Boc)2O,DMAP,THF,0℃to rt,1 h;(c)THF,Py,0℃to rt,3 h.(d)Pd(pph3)4,NaOH,dioxane:(d)H2O(4:1),N2,90℃,反应过夜.(e)Cu(OAc)2,TEA,A molecular sieve,MeCN,80℃,12 h.(f)THF:H2O(2:1),NaOH,60℃,4 h.
反应式3.化合物DC6-9的一般合成路线
反应试剂和反应条件:(a)Phenyl chloroformate,THF,DIPEA,0℃to reflux,8h;(b)DMF,K2CO3,0℃,30 min;(c)i)Pd(pph3)4,K2CO3,dioxane:H2O(4:1),N2,90℃,反应过夜。
1.2.1DC1,2,4合成步骤示例
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(10.15mmol)6-溴吲唑溶于20mL的无水THF,在冰浴下多次少量加入2.28g(20.30mmol)KOtBu,活化10分钟后再加入3.9g(15.37mmol)碘单质。在冰浴下继续反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL双颈瓶,放入搅拌子。称取1.4g(3.32mmol)中间体2,680mg N-乙基哌嗪苯胺,30.4mg(0.00332mmol)Pd2(dba)3,38.4mg(0.00664mmol)Xantphos,2.16g(6.64mmol)碳酸铯。用三通阀抽真空,氮气置换三次,用注射器加入20mL的甲苯,在70℃下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为6h。反应结束后,用EtOAc萃取(3×30mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体3。
(4)化合物D1、D2、D4的合成通法:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物D1、D2、D4。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
1.2.2DC5合成步骤示例
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(10.15mmol)6-溴吲唑溶于20mL的无水THF,在冰浴下多次少量加入2.28g(20.30mmol)KOtBu,活化10分钟后再加入3.9g(15.37mmol)碘单质。在冰浴下继续反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL双颈瓶,放入搅拌子。称取1.4g(3.32mmol)中间体2,680mg N-乙基哌嗪苯胺,30.4mg(0.00332mmol)Pd2(dba)3,38.4mg(0.00664mmol)Xantphos,2.16g(6.64mmol)碳酸铯。用三通阀抽真空,氮气置换三次,用注射器加入20mL的甲苯,在70℃下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为6h。反应结束后,用EtOAc萃取(3×30mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体3。
(4)中间体4的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体4。
(5)DC5的合成:取一个50mL两口烧瓶,取60.8mg(1.2mmol)的LAH,氮气保护,加入15mL的无水THF,在-78℃缓慢加入(0.4mmol)溶于无水THF的中间体4,加完后移至室温后过夜,用TLC监测反应进程判断反应终点。减压浓缩,硅胶柱层析进一步纯化得产物DC5。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
1.2.3DC3,11-13合成步骤示例
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子,将2.02g(10.15mmol)4-溴-2-氟苯甲腈溶于20mL的无水正丁醇,再加入1.015g(20.30mmol)水合肼,于120℃下冷凝回流。用TLC监测反应进程判断反应终点,反应时间一般为5h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL双颈瓶,放入搅拌子。称取1.4g(3.32mmol)中间体2,680mg N-乙基哌嗪苯胺,30.4mg(0.00332mmol)Pd2(dba)3,38.4mg(0.00664mmol)Xantphos,2.16g(6.64mmol)碳酸铯。用三通阀抽真空,氮气置换三次,用注射器加入20mL的甲苯,在70℃下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为6h。反应结束后,用EtOAc萃取(3×30mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体3。
(4)中间体4的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物DC3,DC11-DC13。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
1.2.4DC10合成步骤示例
(1)中间体1的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子,将2.02g(10.15mmol)4-溴-2-氟苯甲腈溶于20mL的无水正丁醇,再加入1.015g(20.30mmol)水合肼,于120℃下冷凝回流。用TLC监测反应进程判断反应终点,反应时间一般为5h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子。将2g(6.21mmol)中间体1溶于20mL的无水THF,加入1.7mL(7.45mmol)二碳酸二叔丁酯和76mg(0.621mmol)DMAP。在室温下搅拌反应。步骤二:用TLC监测反应进程判断反应终点,反应时间一般为2h。反应结束后,用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2。
(3)中间体3的合成:步骤一:取一干净且干燥的50mL圆底烧瓶,放入搅拌子,并加入25mL的无水CH2Cl2。将0.5g(2.44mmol)的1-苯基哌啶-4-羧酸加入反应瓶中,再加入1.113g(2.928mmol)的HATU和0.436(2.928mmol)TEA,30min后加入0.974g(2.44mmol)的中间体2,用TLC监测反应进程判断反应终点。
(4)DC10的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物DC10。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
1.2.3DC6-9合成步骤示例
(1)中间体1的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。加入1mmol(311mg)的3-氨基-6-溴-1H-吲唑-1-羧酸叔丁酯,同时溶于无水THF15mL,再加入100mg的DIEPA,加入搅拌子,冰浴搅拌15min,后逐滴加入1.2mmol的酰氯,同时每隔半个小时点板监测,直至原料点不变或消失。反应结束后用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体1。直接用于下一步。
(2)中间体2的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。再加入15mL的无水DMF于双颈瓶中,冰浴冷却至0℃,再加入1mmol的中间体1和2mmol的K2CO3,反应30min,同时每隔5min点板监测,直至原料点不变或消失。反应结束后用饱和氯化铵溶液淬灭,EtOAc萃取(3×40mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得中间体2,直接用于下一步。
(3)中间体3的合成:步骤一:取一干净且干燥的25mL双颈瓶,放入搅拌子。称取200mg(0.4mmol)中间体3,0.8mmol各种取代基的苯硼酸,9.2mg(0.008mmol)Pd(pph3)4,32mg(0.8mmol)氢氧化钠。用三通阀抽真空,氮气置换三次,用注射器加入10mL的二氧六环和水(4:1)的混合溶剂。在90℃下搅拌反应,过夜。步骤二:反应结束后,用EtOAc萃取(3×20mL),萃取液用饱和食盐水洗,无水MgSO4干燥,减压浓缩,硅胶柱层析进一步纯化得产物DC3,DC11-DC13。浓缩后置于烘箱干燥,待产物干燥后,测量产率,将样品送质谱、核磁验证。待结构确认后,测量熔点与纯度。
1.3实验结果
合成的所有目标化合物结构如下表所示;
合成的包括活性化合物在内的目标化合物的MS、1H NMR和13C NMR等理化数据如下:
N-(2-(diethylamino)ethyl)-3-((6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)amino)benzamide(DC-1)
黄色固体,22.34%yield,m.p:76.5-77.9℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.07(s,1H),9.08(s,1H),8.24(t,J=5.6Hz,1H),8.10(s,1H),7.99(d,J=8.5Hz,1H),7.88(d,J=9.8Hz,1H),7.60(s,1H),7.49(s,1H),7.46(d,J=8.3Hz,1H),7.36–7.27(m,2H),7.22(d,J=7.7Hz,1H),6.86(d,J=8.3Hz,1H),4.58(t,J=8.7Hz,2H),3.26(t,J=8.7Hz,2H),3.17(s,2H),2.59–2.55(m,2H),2.53(s,4H),1.00–0.97(m,7H).ESI-MSm/z:470.3(M+H)+
6-(2,3-dihydrobenzofuran-5-yl)-N-(3-(4-methylpiperazin-1-yl)phenyl)-1H-indazol-3-amine(DC-2)
黄色固体,25.29%yield,m.p:167.0-168.7℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.01(s,1H),8.94–8.58(m,1H),7.98(d,J=7.8Hz,1H),7.58(d,J=6.9Hz,1H),7.41(dd,J=22.3,8.1Hz,3H),7.32–7.20(m,1H),7.10(d,J=9.7Hz,2H),6.93(s,1H),6.84(d,J=7.6Hz,1H),6.40(d,J=6.8Hz,1H),4.55(d,J=7.9Hz,2H),3.23(d,J=7.5Hz,2H),3.11(s,4H),2.46(s,4H),2.21(s,3H).ESI-MSm/z:426.2(M+H)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)furan-2-carboxamide(DC-3)
黄色固体,19.39%yield,m.p:196.3-198.1℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.83(s,1H),10.76(s,1H),7.97(d,J=1.0Hz,1H),7.77(d,J=8.5Hz,1H),7.65–7.63(m,1H),7.61(s,1H),7.56(dd,J=6.9,2.4Hz,1H),7.49–7.47(m,1H),7.34(dd,J=8.6,1.3Hz,1H),6.87(d,J=8.3Hz,1H),6.73(dd,J=3.5,1.7Hz,1H),4.58(t,J=8.7Hz,2H),3.26(t,J=8.7Hz,2H).ESI-MSm/z:346.1(M+H)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-4-(4-ethylpiperazin-1-yl)benzamide(DC-4)
白色固体,25.21%yield,m.p:190.2-191.8℃.1H NMR(400MHz,DMSO-d6)δ(ppm):12.75(s,1H),10.53(s,1H),8.01(d,J=8.8Hz,2H),7.76(d,J=8.5Hz,1H),7.62(s,1H),7.58(s,1H),7.47(d,J=8.2Hz,1H),7.33(d,J=9.4Hz,1H),7.03(d,J=8.9Hz,2H),6.88(d,J=8.3Hz,1H),4.60(t,J=8.7Hz,2H),3.34–3.29(m,4H),3.26(d,J=8.7Hz,2H),2.52(s,4H),2.39(q,J=7.1Hz,2H),1.06(t,J=7.2Hz,3H).13C NMR(126MHz,DMSO-d6)δ(ppm):165.03,159.48,153.14,141.89,138.82,133.03,129.32,128.19,126.87,123.91,122.51,119.76,119.15,115.90,113.38,109.17,106.77,71.17,52.12,51.59,46.97,29.08,11.94.ESI-MSm/z:468.2(M+H)+
6-(2,3-dihydrobenzofuran-5-yl)-N-(4-(4-ethylpiperazin-1-yl)benzyl)-1H-indazol-3-amine(DC-5)
黄色固体,28.39%yield,m.p:130.7-132.3℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.27(s,1H),10.26(s,1H),7.96(d,J=8.5Hz,1H),7.59(s,1H),7.46(s,2H),7.35(d,J=8.6Hz,2H),7.30(d,J=8.6Hz,1H),7.00(d,J=8.6Hz,2H),6.87(d,J=8.3Hz,1H),4.58(t,J=8.7Hz,2H),4.49(s,2H),3.81(d,J=11.8Hz,2H),3.57(d,J=10.9Hz,3H),3.26(d,J=8.7Hz,2H),3.21–3.17(m,2H),3.11(s,2H),2.99(t,J=11.4Hz,2H),1.26(t,J=7.3Hz,3H).13C NMR(126MHz,DMSO-d6)δ(ppm):159.74,158.74,158.47,155.81,148.74,148.70,143.00,132.64,130.73,128.60,128.24,126.95,123.93,121.50,118.66,117.52,115.95,115.18,111.30,109.18,106.85,71.21,50.60,50.10,46.17,45.80,29.01,8.79.ESI-MSm/z:476.2(M+Na)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-4-methylpiperidine-1-carboxamide(DC-6)
白色固体,26.49%yield,m.p:211.7-213.4℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.44(s,1H),8.95(s,1H),7.60(d,J=25.9Hz,2H),7.46(d,J=34.1Hz,2H),7.25(s,1H),6.85(s,1H),4.57(s,2H),4.15(s,2H),3.25(s,2H),2.80(s,2H),1.62(s,3H),1.08(s,2H),0.94(s,3H).13C NMR(126MHz,DMSO-d6)δ(ppm):159.41,155.20,141.88,138.60,133.15,128.16,126.81,123.86,122.34,118.74,116.07,109.14,106.62,71.15,44.13,33.78,30.46,29.07,21.80.ESI-MSm/z:377.2(M+H)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-4-ethylpiperazine-1-carboxamide(DC-7)
白色固体,32.59%yield,m.p:187.1-188.6℃.1H NMR(400MHz,DMSO-d6)δ(ppm):12.54(s,1H),9.07(s,1H),7.66(d,J=8.5Hz,1H),7.59(s,1H),7.52(s,1H),7.45(d,J=8.2Hz,1H),7.28(d,J=8.5Hz,1H),6.87(d,J=8.3Hz,1H),4.59(t,J=8.6Hz,2H),3.53(s,4H),3.26(t,J=8.6Hz,2H),2.41(d,J=5.1Hz,4H),2.37(d,J=6.9Hz,2H),1.05(t,J=7.1Hz,3H).ESI-MSm/z:392.2(M+H)+
tert-butyl6-(2,3-dihydrobenzofuran-5-yl)-3-(2-formyl-1H-pyrrole-1-carboxamido)-1H-indazole-1-carboxylate(DC-8)
白色固体,35.28%yield,m.p:185.2-187.0℃.1H NMR(500MHz,DMSO-d6)δ(ppm):8.15(s,1H),7.88(d,J=8.2Hz,1H),7.64(d,J=6.9Hz,1H),7.62–7.59(m,1H),7.57(d,J=3.5Hz,1H),7.54(dd,J=7.7,2.4Hz,1H),7.50(dd,J=8.3,1.3Hz,1H),7.43(dd,J=8.3,1.7Hz,1H),6.86(d,J=8.3Hz,1H),6.37(s,2H),4.57(t,J=8.7Hz,2H),3.24(t,J=8.7Hz,2H),1.60(s,9H).13C NMR(126MHz,DMSO-d6)δ(ppm):159.78,152.31,141.59,140.73,133.07,132.61,132.26,132.00,131.48,131.41,128.75,128.66,128.36,126.97,123.91,121.49,120.98,117.83,111.39,109.27,82.28,71.23,28.99,27.86.ESI-MSm/z:374.2(掉Boc)
1-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-3-(4-fluorobenzyl)urea(DC-9)
白色固体,28.45%yield,m.p:183.5-185.2℃.1H NMR(400MHz,DMSO-d6)δ(ppm):12.35(s,1H),9.63(s,1H),8.36(s,1H),8.06(d,J=8.6Hz,1H),7.61(d,J=7.3Hz,1H),7.50(s,1H),7.46(d,J=8.3Hz,1H),7.41(dd,J=8.4,5.7Hz,2H),7.29(d,J=8.6Hz,1H),7.19(t,J=8.9Hz,2H),6.87(d,J=8.3Hz,1H),4.59(t,J=8.7Hz,2H),4.47(d,J=5.8Hz,2H),3.26(t,J=8.6Hz,2H).13C NMR(126MHz,DMSO-d6)δ(ppm):162.12,160.20,159.54,155.00,142.27,141.44,139.78,136.31,132.92,131.49,131.41,129.12,129.06,128.90,128.84,128.77,128.67,128.17,126.90,123.94,121.21,118.85,115.15,114.98,114.93,114.76,112.58,109.15,106.47,71.17,42.24,29.06.ESI-MSm/z:403.1(M+H)+
N-(6-(2,3-dihydrobenzofuran-6-yl)-1H-indazol-3-yl)-1-phenylpiperidine-4-carboxamide(DC-10)
灰色固体,13.49%yield,m.p:90.2-91.8℃.1H NMR(400MHz,DMSO-d6)δ(ppm):8.46(s,1H),7.94(d,J=8.1Hz,1H),7.60(s,2H),7.45(d,J=8.3Hz,1H),7.23(t,J=7.5Hz,2H),6.98(d,J=8.1Hz,2H),6.89(d,J=8.2Hz,1H),6.78(t,J=7.2Hz,1H),6.58(s,2H),4.60(t,J=8.6Hz,2H),3.80(d,J=12.2Hz,2H),3.27(t,J=8.6Hz,2H),2.78(t,J=11.8Hz,2H),2.03(d,J=17.0Hz,2H),1.86(t,J=10.7Hz,2H).13C NMR(126MHz,DMSO-d6)δ(ppm):173.36,159.84,152.78,151.08,142.24,140.14,132.41,128.92,128.42,127.04,123.97,122.56,121.00,118.64,115.90,112.40,109.28,71.26,48.30,28.96,27.50.ESI-MSm/z:439.2(M+H)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-4-methoxybenzenesulfonamide(DC-11)
白色固体,21.39%yield,m.p:212.2-214.0℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.63(s,1H),10.50(s,1H),7.72(d,J=8.8Hz,3H),7.57(s,1H),7.50(s,1H),7.42(d,J=8.3Hz,1H),7.32(d,J=8.6Hz,1H),7.05(d,J=8.9Hz,2H),6.85(d,J=8.3Hz,1H),4.57(t,J=8.7Hz,2H),3.80(s,3H),3.24(t,J=8.7Hz,2H).13C NMR(126MHz,DMSO-d6)δ(ppm):162.30,159.54,141.59,139.18,138.48,132.84,131.94,129.07,128.19,126.92,123.94,120.43,119.92,115.87,114.08,109.17,106.89,71.17,55.58,29.06.ESI-MS m/z:422.1(M+H)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-4-methylpiperazine-1-sulfonamide(DC-12)
白色固体,27.31%yield,m.p:194.5-196.3℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.75(s,1H),10.15(s,1H),7.83(d,J=8.5Hz,1H),7.59(s,1H),7.56(s,1H),7.45(d,J=8.2Hz,1H),7.37(d,J=9.7Hz,1H),6.86(d,J=8.3Hz,1H),4.58(t,J=8.7Hz,2H),3.25(t,J=8.7Hz,2H),3.21–3.10(m,4H),2.31(s,4H),2.14(s,3H).13CNMR(126MHz,DMSO-d6)δ(ppm):159.54,141.76,139.23,138.94,132.90,128.20,126.94,123.96,120.55,119.97,115.93,109.18,106.97,71.18,53.76,45.82,45.33,29.07.ESI-MSm/z:414.2(M+H)+
N-(6-(2,3-dihydrobenzofuran-5-yl)-1H-indazol-3-yl)-3-phenylpropanamide(DC-13)
白色固体,31.37%yield,m.p:214.5-216.4℃.1H NMR(500MHz,DMSO-d6)δ(ppm):12.63(s,1H),10.39(s,1H),7.77(d,J=8.5Hz,1H),7.59(s,1H),7.52(s,1H),7.44(d,J=8.3Hz,1H),7.30(t,J=4.8Hz,5H),7.20(dd,J=5.8,3.0Hz,1H),6.86(d,J=8.3Hz,1H),4.58(t,J=8.7Hz,2H),3.25(t,J=8.7Hz,2H),2.98(t,J=7.7Hz,3H),2.73(t,J=7.6Hz,3H).13C NMR(126MHz,DMSO-d6)δ(ppm):170.38,159.49,141.83,141.19,140.23,138.87,132.96,131.42,128.68,128.32,128.29,128.19,126.86,125.94,123.91,122.81,118.99,114.98,109.16,106.64,71.17,38.98,36.92,30.91,29.07.ESI-MSm/z:384.1(M+H)
本发明所合成目标化合物的性状及其溶解性如下:
目标化合物产率普遍较高。化合物DC1-13均为白色絮状固体;化合物易溶于乙酸乙酯、乙腈、二氯甲烷、DMSO、DMF、DMAC;微溶于石油醚、甲醇、乙醇;不溶于甲苯。本发明合成的目标化合物,在MS谱图中均显示了[M+1]+峰,且信号较强,部分化合物存在着同位素峰。1H-NMR谱图结果显示,所有目标化合物的氢信号,以及其化学位移,在图谱上都能清晰的看出。以DMSO-d6为溶剂时,核磁氢谱数据显示完全,即化合物氢的理论个数,与核磁氢谱图上氢的个数相吻合;而以CDCl3为溶剂时,大多数的目标化合物的核磁氢谱数据显示不完全,核磁氢谱图上通常没有脲基胺上的两个氢。13C-NMR谱图结果显示,目标化合物碳峰位移及数目基本上与理论数据相符。
实施例2化合物抗肿瘤细胞活性(激酶实验)
2.1实验操作步骤
(1)配制1×Kinase buffer。
(2)化合物浓度梯度的配制:受试化合物测试浓度为10μM,复孔检测,在384孔板中配置成100倍终浓度的溶液。然后用Echo550转移250nl到384反应板中备用。阴性对照孔和阳性对照孔中分别加250nl的100%DMSO。
(3)用1×Kinase buffer配制2.5倍终浓度的激酶溶液。
(4)在化合物孔和阳性对照孔分别加入10μL的2.5倍终浓度的激酶溶液;在阴性对照孔中加10μL的1×Kinase buffer。
(5)1000rpm离心30秒,振荡混匀后室温孵育10分钟。
(6)用1×Kinase buffer配制25/15倍终浓度的ATP和Kinase substrate的混合溶液。
(7)加入15μL的25/15倍终浓度的ATP和底物的混合溶液,起始反应。
(8)将384孔板1000rpm离心30秒,振荡混匀后室温孵育25分钟。
(9)加入30μL终止检测液停止激酶反应,1000rpm离心30秒,振荡混匀。
(10)用Caliper EZ Reader读取转化率。
(11)加入30μL终止检测液停止激酶反应,1000rpm离心30秒,振荡混匀。用CaliperEZ ReaderⅡ读取转化率。计算公式:Inhibition=(Conversion%_max-Conversion%_sample)/(Conversion%_max-Conversion%_min)*100。其中:Conversion%_sample是样品的转化率读数;Conversion%_min:阴性对照孔均值,代表没有酶活孔的转化率读数;Conversion%_max:阳性对照孔比值均值,代表没有化合物抑制孔的转化率读数。
2.2实验结果
表2:激酶实验结果
2.3实验结果分析
上述激酶实验筛选出了对FGFR 1效果好的化合物,其中DC4的在1μM下对FGFR 1的活性达到了55%。
Claims (4)
1.一种2,3-二氢苯并呋喃基取代的1H-吲唑类化合物,其特征在于,所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物为化合物DC4;
结构式如下:
2.一种如权利要求1所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物在制备抗肿瘤药物中的应用,其特征在于,所述的抗肿瘤药物用于治疗癌症。
3.根据权利要求2所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物在制备抗肿瘤药物中的应用,其特征在于,所述癌症为肺癌。
4.根据权利要求3所述的2,3-二氢苯并呋喃基取代的1H-吲唑类化合物在制备抗肿瘤药物中的应用,其特征在于,所述肺癌为非小细胞肺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111257234.0A CN115322176B (zh) | 2021-10-27 | 2021-10-27 | 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111257234.0A CN115322176B (zh) | 2021-10-27 | 2021-10-27 | 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115322176A CN115322176A (zh) | 2022-11-11 |
CN115322176B true CN115322176B (zh) | 2024-04-16 |
Family
ID=83912896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111257234.0A Active CN115322176B (zh) | 2021-10-27 | 2021-10-27 | 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115322176B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007076092A2 (en) * | 2005-12-23 | 2007-07-05 | Amgen Inc. | Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases |
CN112521336A (zh) * | 2020-02-21 | 2021-03-19 | 温州医科大学 | 一种吲唑类、吡咯并吡啶类化合物及其应用 |
-
2021
- 2021-10-27 CN CN202111257234.0A patent/CN115322176B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007076092A2 (en) * | 2005-12-23 | 2007-07-05 | Amgen Inc. | Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases |
CN112521336A (zh) * | 2020-02-21 | 2021-03-19 | 温州医科大学 | 一种吲唑类、吡咯并吡啶类化合物及其应用 |
Non-Patent Citations (1)
Title |
---|
Design, synthesis , and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer;Xiaolu Chen,等;《European Journal of Medicinal Chemistry》;20210129;第214卷;113219 * |
Also Published As
Publication number | Publication date |
---|---|
CN115322176A (zh) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102459233B (zh) | 二取代的酞嗪hedgehog途径拮抗剂 | |
Zhang et al. | Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors | |
CN110041310B (zh) | 一种伊马替尼衍生物的制备方法和应用 | |
EP3640248A1 (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
CN107383004B (zh) | 2-氨基咪唑并吡啶类衍生物及制备和应用 | |
CN102958921A (zh) | 一种脲类化合物、其制备方法、其中间体及其应用 | |
WO2016150340A1 (zh) | 喹唑啉衍生物的盐及其制备方法 | |
CN114181207B (zh) | β-咔波啉类化合物及其制备方法和抗阿尔兹海默病的应用 | |
CN110563703A (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
TW201904973A (zh) | 作為mek抑制劑的類香豆素環類化合物及其應用 | |
CN116987066A (zh) | 一种嘧啶类化合物及其制备方法和应用 | |
CN109053592B (zh) | 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN115322176B (zh) | 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 | |
Li et al. | Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis | |
CN114105887A (zh) | 一种氨基嘧啶衍生物及其制备方法和用途 | |
WO2018177444A2 (zh) | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 | |
CN114835640B (zh) | 成纤维细胞生长因子受体抑制剂、制备方法及应用 | |
CN115477639B (zh) | 一种以fgfr1为靶点的多取代嘧啶类化合物及其制备方法和用途 | |
CN109053594B (zh) | 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN111057021A (zh) | 均三嗪类化合物及其制备方法和用途 | |
CN113956234A (zh) | 一种n-苯基取代1h-吲唑-3-胺类化合物及其制备和抗肿瘤活性的应用 | |
JP2021508319A (ja) | Akt阻害剤としての塩形態及びその結晶形態 | |
TW201934547A (zh) | 一種嘧啶類化合物、其製備方法及其醫藥用途 | |
CN110734391A (zh) | 2,3-二酮吲哚类化合物及其制备方法与应用 | |
CN110590640B (zh) | 一种靛玉红衍生物及其作为cdk/hdac双靶标抑制剂的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |